-

01:54:52 PM

ENLV Stock News

ENLV - Enlivex Therapeutics Ltd

09/11/23 8:00 AM

Nasdaq : ENLV

earningslow float

Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results

The Company intends to increase its existing focus on inflammatory and autoimmune indications. The Company, since its inception, considered the inherent properties of Allocetra TM as an innovative, highly-differentiated modality for immune resolution across a wide variety of inflammatory and

RHEA-AI

neutral

09/07/23 8:00 AM

Nasdaq : ENLV

conferenceslow float

Enlivex to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will present a corporate update at the H.C. Wainwright 25th Annual Global Investment Conference,

RHEA-AI

neutral

08/02/23 8:00 AM

Nasdaq : ENLV

clinical trialcovid-19low float

Enlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with COVID-19

Data published in Frontiers in Immunology show a robust safety profile and rapid resolution from ARDS and parallel resolution of inflammation markers and elevated cytokines/chemokines, as well as substantial improvements in mortality in 21 Allocetra-treated patients with COVID-19 vs. matched

RHEA-AI

neutral

07/31/23 8:00 AM

Nasdaq : ENLV

clinical triallow float

Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the first patient has been dosed under the amended protocol for the Company’s Phase II trial

RHEA-AI

neutral

06/26/23 8:00 AM

Nasdaq : ENLV

earningslow float

Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update

Enrollment of patients in the Phase I/II evaluating Allocetra™ in combination with chemotherapy in patients with peritoneal metastases from advanced solid tumors is proceeding as planned, with 50% (lower dose cohorts) already enrolled. The integration of tislelizumab, an anti-PD-1 immune checkpoint

RHEA-AI

neutral

06/06/23 8:00 AM

Nasdaq : ENLV

conferenceslow float

Enlivex to Present at the 2023 Jefferies Healthcare Conference

Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will present a corporate update at the 2023 Jefferies Healthcare Conference, which is taking

RHEA-AI

neutral

05/31/23 8:04 AM

Nasdaq : ENLV

low float

Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages, today announced three poster presentations, including a selected Elevator Pitch Presentation

RHEA-AI

neutral

05/08/23 8:00 AM

Nasdaq : ENLV

low float

Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of a European patent, numbered 3865189, entitled, “Combination Immune Therapy and Cytokine

RHEA-AI

neutral

04/19/23 8:00 AM

Nasdaq : ENLV

low float

Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages, today announced that the U.S. Patent and Trademark Office issued a Notice of Allowance for

RHEA-AI

neutral

04/17/23 8:00 AM

Nasdaq : ENLV

managementlow float

Enlivex Appoints Andrew Singer to its Board of Directors

Mr. Singer brings over 25 years of experience in biotechnology, corporate finance, mergers and acquisitions, and business strategy Former EVP and CFO of Epizyme and Senior Biotech Investment Banker at Credit Suisse, Wells Fargo Securities and RBC Capital Markets Led financing, partnering and M&A

RHEA-AI

very positive

1 2 3 4 5 6 7 8 9 10 Next

ENLV Data

IndustryPharmaceutical Preparation Manufacturing
Websitehttps://www.enlivex.com/
Security nameEnlivex Therapeutics Ltd
SectorManufacturing
Tags
- Biotechnology
- Medical Specialties
- Health Technology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
CountryIsrael

About Enlivex Therapeutics Ltd

enlivex therapeutics ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. its product candidate is allocetra, an immunotherapy candidate, which is in phase iib clinical trial in patients with severe sepsis; that is in investigator-initiated phase ii clinical trial for the treatment of covid-19 patients in severe and critical conditions; and which is in phase iia clinical trial for the prevention of graft versus host disease in allogeneic hematopoietic stem cell transplants (hsct) patients. the company is also developing allocetra for the prevention of complications associated with bone marrow transplantations and/or hsct, and acute multiple organ failure. it also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor t-cell therapy and therapies targeting t-cell re